Q32 Bio (STU:DB0) Volatility: 125.54% (As of Jun. 25, 2026)


STU:DB0 Q32 Bio Inc STU:DB0
17 GF Score
Price €9.65
! 2 Warning Signs
View Full Analysis

What is Q32 Bio Volatility?

Q32 Bio STU:DB0 -5.76% 17 Volatility is 125.54% as of Jun. 25, 2026. GuruFocus rates STU:DB0 with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Q32 Bio's Volatility is 125.54%.


Q32 Bio  (STU:DB0) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Q32 Bio Volatility Related Terms


STU:DB0 vs ABOS, TNYA, MDWD: Volatility Comparison

For the Biotechnology subindustry, Q32 Bio's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Volatility distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Volatility falls into.


STU:DB0
17GF Score
Q32 Bio Inc STU:DB0
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio  (STU:DB0) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 125.54% mean?
Q32 Bio (STU:DB0) has a Volatility of 125.54% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Q32 Bio and its competitors.
Is Q32 Bio's Volatility too high?
Q32 Bio's current Volatility is 125.54%. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Volatility compare to ABOS and TNYA?
Q32 Bio's Volatility of 125.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Q32 Bio and its competitors. Q32 Bio's current Volatility is 125.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (STU:DB0) has a current Volatility of 125.54%. The current Volatility is 125.54%. Q32 Bio's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Q32 Bio (STU:DB0), the current Volatility is 125.54% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USADB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for STU:DB0

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.65
Price